Back to search

Article

The Utility of Genomics and Functional Imaging to Predict Sunitinib Pharmacokinetics and Pharmacodynamics: The Predict Su Study

2023-06-26

Abstract excerpt

<h4>Purpose: </h4> Sunitinib has marked pharmacokinetic (PK) & pharmacodynamic (PD) interpatient variability. This study evaluated the utility of extensive excretory/metabolic/PD pharmacogenomics (PGx) with hepatic functional imaging (HNI) to explore associations with Sunitinib PK/PD (toxicity/response) and progression-free survival (PFS). <h4>Methods: </h4>: Eligible patients (pts) suitable for Sunitinb therapy....

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
d779bd39-d46d-59b1-888f-6f6328931408
DOI
10.21203/rs.3.rs-3069721/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The Utility of Genomics and Functional Imaging to Predict Sunitinib Pharmacokinetics and Pharmacodynamics: The Predict Su StudyDOI 10.21203/rs.3.rs-3069721/v1
Pharmacogenomics and functional imaging to predict irinotecan pharmacokinetics and pharmacodynamics: the predict IR study.Semantic proximity
Genetic biomarkers of sorafenib response in patients with hepatocellular carcinomaSemantic proximity
Genetic polymorphisms as predictive biomarker of survival in patients with gastrointestinal stromal tumors treated with sunitinib.Semantic proximity
Genetic polymorphisms of VEGFR2 and FGFR2 genes are associated with exposure to sunitinib and cardiovascular toxicity.Semantic proximity
Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer.Semantic proximity
Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.Semantic proximity
Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study.Semantic proximity
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.Semantic proximity
Effects of single nucleotide polymorphisms on treatment outcomes and toxicity in patients treated with sunitinib.Semantic proximity
Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patientsSemantic proximity
Evaluation of pharmacogenomics and hepatic nuclear imaging-related covariates by population pharmacokinetic models of irinotecan and its metabolites.Semantic proximity
Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662.Semantic proximity
Select a neighboring publication to make it the new centre.